In addition to enhancing the efficacy of pegylated interferon alfa, the addition of ribavirin to the treatment regimen also increases the
side effects associated with combination therapy. The most important
side effect of
ribavirin is anemia, which is predominantly related to a hemolytic process. Another therapeutic agent, taribavirin,* an oral prodrug of ribavirin, was developed in an attempt to reduce this potentially serious side effect.